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The pathogenesis of Crohn’s disease (CD) and ulcerative colitis (UC), the two main forms of
inﬂammatory bowel disease (IBD), is still unclear, but both autoimmune and immune-mediated
phenomena are involved. Autoimmune phenomena include the presence of serum and mucosal
autoantibodies against intestinal epithelial cells in either form of IBD, and against human tropomyosin
fraction ﬁve selectively in UC. In addition, perinuclear antineutrophil cytoplasmic antibodies (pANCA)
are common in UC, whereas antibodies against Saccharomyces cerevisiae (ASCA) are frequently
found in CD. Immune-mediate phenomena include a variety of abnormalities of humoral and cell-
mediated immunity, and a generalized enhanced reactivity against intestinal bacterial antigens in both
CD and UC. It is currently believed that loss of tolerance against the indigenous enteric ﬂora is the
central event in IBD pathogenesis. Various complementary factors probably contribute to the loss of
tolerance to commensal bacteria in IBD. They include defects in regulatory T-cell function, excessive
stimulation of mucosal dendritic cells, infections or variants of proteins critically involved in bacterial
antigen recognition, such as the products of CD-associated NOD2/CARD15 mutations.
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INTRODUCTION
Chronic inﬂammatory diseases where an external
infectious or noxious agent is not readily identiﬁed as
the direct cause of the associated pathology are usually
categorized as autoimmune or immune-mediated con-
ditions. This implies a dominant role of the immune
system in triggering and maintaining an inﬂammatory
response against known or unknown antigens that are part
of the host or intimately associated with it. In reality,
chronic disabling inﬂammatory diseases of uncertain
etiology are the result of highly complex and intimately
integrated biological networks that also include genetic,
environmental and neuroendocrine components (Straub
and Besedovsky, 2003). This concept also applies to
Crohn’s disease (CD) and ulcerative colitis (UC), two
chronic inﬂammatory conditions of the gastrointestinal
tract that are collectively known as inﬂammatory bowel
diseases (IBD). There is considerable evidence demon-
strating that immunopathogenic events are distinct in CD
and UC (Fiocchi, 1998; Podolsky, 2002; Bouma and
Strober, 2003), but these entities also share plausible
pathogenic factors such as dietary antigens and the enteric
commensal ﬂora. The latter, in particular, has received a
great deal of attention in the last decade due to mounting
evidence that it may function as a “self-antigen” in IBD,
a notion that will be discussed later on. Still in regard to
the role of the enteric ﬂora, when discussing organ-
speciﬁc autoimmune or immune-mediated pathogenesis,
a fundamental concept that cannot be overemphasized is
that both CD and UC occur in a non sterile, “dirty” tissue
environment, unlike any other type of autoimmune or
immune-mediated disorder that develops in sterile,
“clean” tissues, such as the joint in rheumatoid arthritis,
the nervous system in multiple sclerosis, the thyroid in
autoimmune thyroiditis, the bile ducts in primary biliary
cirrhosis, the microcirculation in systemic lupus erythe-
matosus, and so on. This crucial difference between IBD
and other immunological conditions is at the core of the
present review, and will allow us to consider the intriguing
idea of the normal enteric ﬂora not as an external
environmental factor but an intrinsic, “self-component” of
the intestine-speciﬁc immune response occurring in CD
and UC.
AUTOIMMUNE EVENTS IN IBD
Classical criteria deﬁning an autoimmune disease include
the demonstration of B-cell clones producing polyreactive
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pathogenic autoantibodies, T-cell clones that are speciﬁc
for autoantigens and can transfer autoimmune disease, the
precise identiﬁcation of organ-speciﬁc autoantigens, and
the reproduction of autoimmune diseases in experimental
animal models (Rose and Bona, 1993). In addition, we
know that autoimmune diseases are conditioned by
genetic and environmental factors (Marrack et al.,
2001), and among the latter a variety of infectious agents
have been demonstrated to possess the ability to induce or
activate autoreactive immune cells (Wucherpfennig,
2001). Molecular mimicry has been invoked as one of
the mechanisms responsible for the activation of
autoreactive cells by microbial peptides that have
structural similarities to self-peptides (Wucherpfennig,
2001), but there is also evidence that antigenically
unrelated infections or speciﬁc inﬂammatory signals can
result in autoaggressiveness and induction of organ-
speciﬁc autoimmunity, including in the gut (Vezys and
Lefranc ¸ois, 2002). Neither CD nor UC fulﬁll all or most of
the criteria for classical autoimmunity. On the other
hand, there is evidence that autoimmune reactivity does
occur in IBD.
Autoantibodies
The ﬁrst reasonable indication that the immune system
was involved in the pathogenesis of IBD emerged in the
late 1950s and early 1960s with the demonstration of
autoantibodies and cytotoxic leukocytes for colonic
epithelial cells in UC patients (Broberger and Perlmann,
1959; Perlmann and Broberger, 1963). Soon after, serum
antibodies against colonic epithelium were detected in the
circulation of UC patients that were cross-reactive with
Escherichia coli antigens, and the hypothesis was
proposed that such immune cross-reactivity could
represent a form of autoimmunity relevant to IBD
pathogenesis (Perlmann et al., 1967). These initial reports
were followed by a long series of studies demonstrating
that both CD and UC patients possess antibodies against a
range of potential autoantigens, including lymphocyte
antigens (Korsmeyer et al., 1974), cytoskeletal proteins
(Mayet et al., 1990), cardiolipin (Aichbichler et al., 1999)
and pancreatic proteins (Fricke et al., 1999).
Additional evidence for the possible involvement of
antibody-dependent pathophysiology in IBD was intro-
duced by the demonstration of alterations of serum
immunoglobulins and the presence of rheumatoid factor
and anti-F(ab0)2 autoantibodies (MacDermott et al., 1981;
Pallone et al., 1986), as well as circulating complement-
ﬁxing immune complexes in the serum of CD and UC
patients (Doe et al., 1973; Jewell and McLennan, 1973).
Moreover, activated complement was located in the
microvessels of IBD-involved mucosa (Halstensen et al.,
1989), and also in the gut epithelium in association with
IgG1 antibodies (Halstensen et al., 1993). Based on these
observations, the question of whether IBD could be a true,
autoantibody-dependent autoimmune disorder was raised
(Thayer, 1976; Snook, 1990), even though convincing
veriﬁcation for the existence of organ-speciﬁc pathogenic
autoantibodies had not been obtained.
Autoantibodies to Intestinal Epithelial Antigens
The search for gut-speciﬁc autoantibodies has been
relatively limited in IBD, and only two lines of
investigation have yielded reasonable evidence suggesting
that true autoantibodies may contribute to IBD
pathogenesis.
Goblet cell glycoproteins, termed epithelial cell-
associated components (ECAC), were initially identiﬁed
in the rat intestine and later in the human intestine (Roche
et al., 1981; Aronson et al., 1983), and the detection of
ECAC-speciﬁc reactivity by circulating mononuclear
cells and sera from CD and UC patients suggested that
autosensitization to these protein had occurred in subjects
with IBD (Aronson et al., 1983). Antigen-speciﬁc
reactivity against ECAC was later demonstrated using
mononuclear cells isolated from CD and UC mucosa
(Roche et al., 1985). These mucosal cells were shown to
be CD3þ lymphocytes, which induced antibody-
mediated cytotoxicity for small or large bowel-derived
ECAC but not control antigens (Roche et al.,1985). These
ﬁndings, including the localization of the antigen(s) to
goblet cells and apparent antigen-speciﬁc immune
reactivity, were recapitulated in the cotton top tamarin, a
spontaneous model of IBD resembling UC (Winter et al.,
1989). These observations have not been followed by
further biochemical characterization of the putative
autoantigens or the mechanisms of autosensitization, and
the importance of ECAC as a pathogenic autoantigen in
IBD remains undeﬁned.
Another series of studies has pursued a different
potential autoantigen which, unlike ECAC, appears to be
large bowel- and disease-speciﬁc. IgG antibodies eluted
from the colonic mucosa of UC patients, but not from
patients with CD or other colonic inﬂammatory con-
ditions, were found to recognize a 40kDa protein present
exclusively in large bowel tissue, suggesting the
possibility that such protein could represent an autoanti-
gen mediating an antibody-mediated response in UC
patients (Takahashi and Das, 1985). The generation of
monoclonal antibodies against the 40kDa protein
permitted to deﬁne its exclusive localization to epithelial
cells of the human large bowel, and not upper or small
bowel, liver, pancreas or non gastrointestinal tissues (Das
et al., 1987). Interestingly, IgG1 and activated comp-
lement were found to colocalize with the 40kDa on
colonocytes of UC but not CD patients (Halstensen et al.,
1993). Follow up studies showed that the epitope
recognized by the monoclonal antibodies in human
colon was selectively present in skin, eye, joint and
biliary epithelium (Das et al., 1990; Bhagat and Das,
1994; Mandal et al., 1994). This localization is extremely
intriguing because those tissues match exactly the sites
where the major extra-intestinal manifestations of IBD
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immune cells sensitized to the 40kDa colonic protein
could cross-react with the same epitope in other locations,
trigger local pathology and explain the extraintestinal
manifestations of IBD (Das, 1999). Further investigation
revealed that lamina propria mononuclear cells isolated
from UC mucosa spontaneously produced IgG1 against
the putative autoantigen (Biancone et al., 1995), that has
now been identiﬁed as a cytoskeletal protein of the
tropomyosin family, speciﬁcally human tropomyosin
fraction 5 (huTM5) (Das et al., 1993; Geng et al.,
1998). Studies in animal models of IBD have yet to be
performed to further substantiate the disease-causing
potential of huTM5, and studies are under way to
understand how this intracellular protein may be
transported to the colonocyte surface to act as a target
self-antigen. Thus, as is the case of ECAC, the true
signiﬁcance of huTM5 as a pathogenic autoantigen and
the related mechanisms of colon inﬂammation are still
uncertain.
pANCA and ASCA
In addition to epithelial-cell autoantibodies, two other
types of antibodies were commonly detected in IBD
patients: antineutrophil cytoplasmic antibodies (ANCA)
and anti-Saccharomyces cerevisiae antibodies (ASCA),
which are relatively speciﬁc for UC and CD, respectively.
In the original report, sera from the majority of patients
with UC were found to contain antibodies recognizing an
antigen(s) with a nongranular perinuclear (p) distribution
in neutrophils (Saxon et al., 1990). The UC-associated
pANCA were distinct from the ANCA found in
Wegener’s granulomatosis or crescent glomerulonephri-
tis, and did not react with myeloperoxidase, suggesting
that they may “UC-speciﬁc”. In subsequent studies, the
levels of pANCA in UC were consistently found to be
signiﬁcantly higher than those of patients with CD,
infectious colitides, irritable bowel syndrome and mis-
cellaneous diarrheal diseases, with a sensitivity of
pANCA for UC of around 60% with a speciﬁcity of
80–90% (Duerr et al., 1991). These values were based on
mostly white North American patients with UC, but are
lower in other European or Asian populations (Sugi et al.,
1999). Of interest, pANCA are present in the circulation of
some animal models of experimental colitis, such as the
interleukin (IL)-10-deﬁcient and the T-cell receptor
(TCR) a-deﬁcient mice (Mizoguchi et al., 1997; Seibold
et al., 1998). The neutrophil antigen(s) recognized by
pANCA is still a matter of dispute, but it is clearly
different from that associated with vasculitis. However,
the answer to the more fundamental question of whether
these autoantibodies are pathogenic and can induce gut
inﬂammation appears to be a negative one. In fact, levels
of pANCA in UC are not correlated to disease activity or
extent, do not affect neutrophil function, patients can have
UC without developing pANCA, and pANCA also occur
in unaffected relatives of UC patients (Shanahan, 1994).
However, pANCA may still be useful as serological
markers of disease, possible markers of genetic suscep-
tibility, or markers for disease heterogeneity.
At the same time that pANCA emerged as UC-
associated autoantibodies, an association of CD with
ASCA was also being investigated. Levels of serum
antibodies against multiple strains of S. cerevisiae
(baker’s and brewer’s yeast) were found to be signiﬁcantly
elevated in the serum of CD patients, but not serum
of UC patients (McKenzie et al., 1990; Giaffer et al.,
1992). This was initially proposed as potentially
indicating hypersensitivity to dietary antigens in CD.
This hypothesis has not been pursued to any signiﬁcant
extent and is still a theoretical possibility, but it is well
established that ASCA recognize mannose sequences in
the cell wall mannan of S. cerevisiae, deﬁning ASCA as a
non autoantigen in IBD. Although not totally speciﬁc for
CD, as ASCA can be detected in serum of some celiac
disease patients (Giaffer et al., 1992), the lack of
antibodies in the circulation of UC patients suggested
that the combined measurement of pANCA and ASCA
could help in the differential diagnosis of the two forms of
IBD, a typically challenging situation for the practicing
gastroenterologist. Two studies, one performed with adult
and the other with pediatric subjects in which sera from
UC and CD patients were assessed for both pANCA and
ASCA, showed that the combination of a positive pANCA
and a negative ASCA was highly speciﬁc (95–100%) for
UC, whereas the combination of a negative pANCA and a
positive ASCA was highly speciﬁc (95–100%) for CD
(Ruemelle et al., 1998; Quinton et al., 1998). These
results have been replicated in multiple reports, but
unfortunately all studies agree that the sensitivity of the
combined pANCA plus ASCA test is still too low (around
50–60%) to be useful as general screening tool.
IMMUNE-MEDIATED EVENTS IN IBD
Immune Abnormalities in IBD
Taking into consideration all the information discussed so
far, it is apparent that data favoring classical autoimmune
pathogenic mechanisms, like antigen-speciﬁc autoreactive
T- or B-cells, are scant and not necessarily robust in IBD.
On the other hand, there is an overwhelming amount of
data proving that abnormalities of the mucosal and
systemic immune systems are intimately involved in the
pathogenesis of both CD and UC. As indicated earlier,
these abnormalities are almost certainly secondary, and
occur in the context of other sine qua non conditioning
factors, which include genetic predisposition, environ-
mental changes, and the intestinal ﬂora (Fiocchi, 1998;
Podolsky, 2002). Most of the immune abnormalities
describedinthelasttwodecadesofinvestigationhavebeen
focused on mucosal immune events, particularly searching
for imbalances or skewing of the Th1/Th2
paradigm(Neurathet al.,2002).Althoughthedownstream
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predictably characterized by the production of high levels
of cytokines, growth factors, free radicals and matrix-




high IL-12, IL-18 and interferon (IFN)-g production
(Monteleone et al., 1997), whereas UC has been very
recently deﬁned as an atypical Th2 response mediated by
CD1d-restricted NK T-cells that produce high levels of
IL-13 (Fuss et al., 2004). Thus, the immune aberrations
underlying the two main forms of IBD are clearly diverse.
Thisconclusion,however,doesnotprecludethepossibility
thattriggeringphenomenaorsensitizingagentsaresimilar,
if not the same. In fact, accumulating evidence derived
from genetic, microbial and immunological observations
strongly suggests that the normal indigenous ﬂora of the
intestinemaybeatthecenterofpathogeniceventsinIBD,a
major point that will be the focus of the following
discussion.
The Intestinal Flora as a Tolerizing “Self-antigen”
Bacteria are usually regarded as microorganisms derived
from the surrounding environment that have the capacity
to invade the host and eventually cause disease. In reality,
the body harbors huge quantities of non-pathogenic
“friendly” bacteria, the vast majority of which are located
within the intestinal lumen. The gut contains at least 400
different species of mostly anaerobic bacteria, and the
number of microbial cells in the lumen is approximately
ten times greater than that of the eukaryotic cells in the
human body. This enormous amount of enteric microbes
constantly and intimately interacts with the host and
confers beneﬁts that are essential to health and survival
(Guarnier and Malagelada, 2003). DNA microarray
analysis of the effect of colonization of germ-free mice
with the Bacteroides thetaiotaomicron,ad o m i n a n t
component of normal human and murine ﬂora, shows
that this bacterium modulates expression of genes
involved in intestinal nutrient absorption, mucosal barrier
function, xenobiotics metabolism, angiogenesis and
postnatal maturation (Hooper et al., 2001). Not only the
intestinal ﬂora provides metabolic, trophic and protective
functions to the host,but is also critical to the development
of normal immunity by affecting the timing, maturation
and composition of the mucosal immune system (Cebra
et al., 1998). Therefore, when intestinal colonization
starts right after birth, the immune system learns to
recognize bacteria and discriminate between commensal
and potential pathogenic microorganisms. This is
accomplished primarily by the innate immune system
through toll-like receptors (TLR), surface structures that
function as mammalian pattern-recognition receptors and
are essential for the detection of microbial components
(Takeda et al., 2003). In addition to innate immunity,
adaptive immunity to enteric bacteria will also develop.
In order to survive and thrive in a potentially hostile
environment, bacteria have developed strategies that
overcome the host’s innate and adaptive immune
responses, which include evasion of immune recognition,
resistance to antibacterial epithelial effect molecules,
escape from phagocyte responses, interference with
antigen presentation, and inhibition of T- and B-cell
functions (Hornef et al., 2002). As a counterpart, the local
mucosal immune system must learn to recognize the
commensal enteric ﬂora without destroying it. When
genetically normal mice kept in a germ-free environment
are given food mixed with fecal pellets from congenic
mice containing normal ﬂora, they develop an acute self-
limited colitis which resolves quickly and is followed by
the induction of a variety of small and large intestine-
speciﬁc genes (Ogawa et al., 2000). This suggests that
when bacteria are ﬁrst introduced in the gut they function
as foreign antigens and induce an inﬂammatory response.
Later, once recognized and found to be non pathogenic,
the local immune cells no longer attack the bacteria with
the intent to destroy them, and both enter a state a peaceful
symbiotic co-existence. This can be viewed as similar to
what happens when the immune system encounters a self-
antigen that is a normal body component and toward
which has already developed tolerance. Thus, a funda-
mental aspect of commensal host-bacterial relationships in
the gut is the development and maintenance of immune
tolerance to the gut enteric ﬂora (Hooper and Gordon,
2001). Therefore, although the commensal gut ﬂora
technically is a foreign antigen, under physiological
circumstances it behaves as a “self-antigen”, and is
perceived as such by the host immune system. Based on
this concept, if tolerance to the gut commensal ﬂora is lost,
this becomes a pathogenic event that may lead to a state of
chronic intestinal inﬂammation.
Failure to Regulate Reactivity to the Gut Flora:
A Central Event in IBD Pathogenesis?
There is mounting evidence that IBD represents a
condition where the normal homeostatic balance between
the enteric ﬂora and mucosal immunity is lost, resulting in
the chronic inﬂammatory response that typiﬁes CD and
UC. Three scenarios can be envisioned that might
explain this outcome: ﬁrst, the quantitative or qualitative
composition of the ﬂora has changed; second, the immune
response towards the normal gut ﬂora is abnormal; third,
the regulatory mechanisms that control ﬂora-host
interaction have gone away.
The Intestinal Flora in IBD
The complexity of the human gut ﬂora has long
represented a major obstacle to the full characterization
of the innumerous microorganisms scattered all along the
gastrointestinal tract. Nevertheless, the major groups of
aerobic and anaerobic bacteria are known, and their
progressivenumerical increase from the upper to the lower
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The complexity of the gut ﬂora rapidly increases after
birth, and by the age of one year its composition resembles
that of an adult person (Favier et al., 2002). There are also
observations indicating that, even though gut bacteria are
relatively stable throughout the life of an individual, each
person has a customized ﬂora and that variations in
bacterial composition occur depending on feeding (breast
milk vs. bottle), different environments, and use of
antibiotics, prebiotics and probiotics.
Recent reports have indicated that a relationship exists
between the composition of the intestinal microﬂora and
the propensity to suffer from allergic inﬂammation
(Kirjavainen et al., 2002), and there are differences in
gut microbiota between infants who will and those who
will not develop allergies even before the appearance of
any clinical manifestations of atopy (Bjorksten et al.,
2001). The same may be true for IBD, as suggested by
prospective studies showing that children with an
abnormal ﬂora have a greater chance of developing CD
than children with a normal ﬂora (VandeMerwe et al.,
1988). These results are compatible with two important
concepts previously introduced: that the gut ﬂora
participates of the education of systemic and mucosal
immunity, and that an altered ﬂora may lead to an aberrant
immune response. There are few studies that have
analyzed the microﬂora of adults with established IBD,
but it appears that both quantitative and qualitative
differences are present in both CD and UC patients.
In patients with UC there is a signiﬁcant decrease in the
number of anaerobic bacteria, anaerobic gram-negatives
and lactobacilli (Fabia et al., 1993), while in CD patients
there is a signiﬁcant increase in enterobacteria indepen-
dent of the clinical activity of disease (Seksik et al.,2003).
In addition, the total number of bacteria found in the
colonic mucus of IBD patients is signiﬁcantly increased
compared to controls (Schultsz et al., 1999), and this
number increases with the severity of mucosal inﬂam-
mation (Swidsinski et al., 2002). Together, these obser-
vations support the notion that alteration of the gut
commensal ﬂora may change its immune recognition from
a “self-antigen” to a new or foreign antigen towards which
the local immune system may mount a response which is
manifested as IBD.
Enhanced Reactivity to Bacterial Antigens in IBD
The possibility that patients with IBD develop an aberrant
immune response against components of the gut ﬂora has
been under consideration for a long time. A number of
reports show that CD and UC patients have increased titers
of antibodies against E. coli, aerobes, anaerobes and even
enteric bacterial pathogens, and that these antibodies are
of both systemic and mucosal origin (Monteiro et al.,
1971; Tabaqchali et al., 1978; Blaser et al.,1 9 8 4 ;
Macpherson et al., 1996). The previously discussed
ASCA in CD patients probably reﬂect the same type of
broad anti-microbial reactivity associated with IBD
(McKenzie et al., 1990; Giaffer et al., 1992). More
recently, novel gut bacterial antigens have been reported
in association with IBD, including the Pseudomonas
ﬂuorescens-associated sequence I2, the outer membrane
porin C of E. coli (OmpC), and bacterial ﬂagellins,
towards which CD patients develop signiﬁcantly higher
antibody titers than UC or control subjects (Sutton et al.,
2000; Landers et al., 2002; Lodes et al., 2004). Interest-
ingly, it has been suggested that the higher the antibody
responses against bacteria and more numerous the
antigens against which they react, the more likely it is
that CD patients will experience a more severe clinical
course, as indicated by a greater frequency of strictures,
perforations, and surgical interventions (Mow et al.,
2004). If conﬁrmed, this observation would indicate that
the greater the level of sensitization to enteric bacteria, the
stronger and more damaging the ensuing mucosal immune
response might be.
Fewer data are available on the cell-mediated immune
response to bacterial antigens in IBD. The existing reports
also indicate that there is an enhanced T-cell reactivity
against microbial antigens of enteric and non enteric
origin in IBD, particularly in CD patients, at both the
systemic and intestinal mucosa level (Bull and Ignaczak,
1973; Pirzer et al., 1991; Young et al., 1994; Duchmann
et al., 1999). Supporting evidence for sensitization to
bacterial antigens in IBD can also be found in animal
models of experimental colitis, where CD4þ T-cells
reactive against enteric ﬂora are detected in both the
spleen and the colon, and they can transfer IBD in
adoptive transfer experiments in SCID mice (Cong et al.,
1998; Wirtz et al., 1999). In addition, it is worth noticing
that some enteric antigens like I2, to which enhanced
humoral immune responses are found in IBD, also
function as superantigens (Dalwadi et al., 2001), and
non enteric superantigens like Staphylococcus aureus
enterotoxin B, or enteric superantigens like Yersinia
pseudotuberculosis can activate T-cells and elicit or
aggravate gut inﬂammation of which they are not the
causative agents (Lu et al., 2003).
Abnormal Regulation of Anti-bacterial Reactivity in
IBD: Loss of Tolerance to the Enteric Flora
While the above-mentioned studies certainly indicate that
abnormal immune reactivity to bacteria is intimately
associated with IBD pathogenesis, the essential role of the
luminal microbiota in triggering or maintaining IBD was
only conﬁrmed with the use of animal models in which the
presence, quantity and type of the ﬂora could be
experimentally controlled and manipulated. The report
that a germ-free condition prevents development of gut
inﬂammation in HLA-B27 transgenic rats was the ﬁrst to
bring attention to the fact that experimental IBD is
dependent on the presence of intestinal bacteria (Taurog
et al., 1994). This seminal observation was followed
by others showing that the luminal bacterial load and
its composition together determine the degree of
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dissimilar proinﬂammatory capacities, that vary from
potent to moderate to absent depending on the genetic
background of the host (Rath et al., 1999a,b). The
observation that IBD fails to develop in the absence of
enteric ﬂora has now been conﬁrmed in numerous animal
models of IBD, and has lead to the widely accepted
paradigm “no bacteria, no colitis”.
If the commensal gut ﬂora is required to develop IBD,
and an inappropriately strong immune response against it
is a key mechanism responsible for the development of
chronic intestinal inﬂammation, how does such damaging
immune response develop? One possibility, already
discussed, is that the antigenic properties of the ﬂora
have changed and an immune response is mounted towhat
previously was a “self-antigen” towards which tolerance
had been established. The reverse possibility is that the
ﬂora is not signiﬁcantly altered in IBD, but the normal
state of tolerance to luminal bacterial antigens has been
lost (Khoo et al.,1 9 9 7 ) .I nr e g a r dt ot h es e c o n d
possibility, a classical study revealed that human
peripheral blood and mucosal mononuclear cells fail to
proliferate when exposed to bacteria from autologous
intestine, but do so after exposure to bacteria from
heterologous intestine, indicating that tolerance to the
autologous gut microbiota normally exists (Duchmann
et al., 1995). In contrast, mucosal immune cells from
active CD or UC patients vigorously proliferate after
co-culture with bacteria from the autologous intestine,
indicating that tolerance is lost in IBD. Similar ﬁndings
were seen in a hapten-induced model of experimental IBD
(Duchmann et al., 1996). Whether loss of tolerance in
IBD is broadly directed to the whole ﬂora or only some
components of it is not clear yet, but the presence of
quantitatively and qualitatively different antibodies to
multiple microbial antigens in various patients subsets
suggests that a selected, rather than a global, loss of
tolerance occurs in IBD (Landers et al., 2002). The extent
and severity of this loss of tolerance is still being deﬁned,
as it has been recently demonstrated that loss of tolerance
in IBD patients is not exclusive for bacterial antigens and
occurs also to orally administered soluble proteins (Kraus
et al., 2004).
Potential Mechanisms Contributing to the Loss of
Tolerance in IBD
The exact cause for the loss of tolerance in IBD is not
known. This is an extremely active area of investigation
and speciﬁc mechanisms are under consideration, some of
which will be brieﬂy discussed.
Lossoftolerancecanbeviewedasaninadequatefunction
of immunoregulatory cells. This rather traditional view has
gained considerable strength with the identiﬁcation of
speciﬁc subsets of immunoregulatory cells, among which
inducible type 1 T regulatory cells (Tr1) and spontane-
ously occurring FOXP3þCD4þCD25þ regulatory cells
ﬁgure prominently (Roncarolo et al., 2001; Bach, 2003).
There is substantial evidence, primarily from animal
models of IBD, that regulatory T cell are involved in the
controlofintestinalinﬂammation(TomsandPowrie,2001).
CD4þ, IL-10-secreting Tr1 cells suppress antigen-speciﬁc
immune responses and actively prevents experimental
colitis (Groux et al., 1997), and CD4þ CD25þ regulatory
T-cells can cure established murine colitis through
mechanisms involving cell-to-cell contact as well as IL-10
and transforming growth factor b1( M o t t e tet al.,2 0 0 3 ) .
Several laboratories are presently investigating the function
of immunoregulatory T-cells in humans with IBD,
and defects in the number or activity of these cells are
likely to emerge in CD or UC patients. However, even after
detection,thetruesigniﬁcanceofimmunoregulatorydefects
in IBD will be difﬁcult to interpret and ﬁt into IBD
pathogenesis because of the intricate and mutual regulatory
networks between regulatory T-cells and other immune
cells, and the complex nature of bacterial antigen
recognition. For instance, microbial activation of TLR on
dendritic cells (DC) can block the suppressor effect of
CD4þ CD25þ regulatory cells and allow a pathogen-
speciﬁc immune response to occur (Casare and Medzhitov,
2003). On other hand, CD4þ CD25þ T-cells can
restrain the maturation and antigen-presenting function of
DC (Misra et al., 2004), which, as mentioned below,
will affect their capacity of recognize and respond to
bacterial stimuli.
Dendritic cells are a heterogeneous population of bone
marrow-derived antigen-presenting cells that inﬂuence
essentially all aspects of innate and acquired immunity
(Liu, 2001). They sense the surrounding microbial
environment through TLR, and signaling through
different TLR generates distinct biological responses,
which vary from excitatory to suppressive. In the intestine
DC are found scattered in all lymphoid compartments,
displaying distinct properties and functions (Staag et al.,
2003), and can penetrate the space in between epithelial
cells and sample lumenal bacteria that they subsequently
present to immune cells in the mucosa (Rescigno et al.,
2001). It is now generally believed that DC are critical to
the balance between tolerance and active immunity and,
because intestinal DC appear to be excessively activated
in IBD (Staag et al., 2003), it is possible that their
function is skewed towards active immunity rather than
tolerance.
Due to the persistent and massive presence of the
commensal ﬂora, intestinal epithelial cells may have
adapted by developing mechanisms that avoid activation
by TLR-dependent microbial signals with a pro-
inﬂammatory potential. In support of this hypothesis
recent reports show that human intestinal epithelial cells
are broadly unresponsive to ligation of TLR2, which
recognizes Gram-positive cell wall components such as
peptidoglycan and certain lipoproteins (Melmed et al.,
2003). In addition, while short term stimulation with
bacterial lipolysaccharide or lipoteichoic acid activates
pro-inﬂammatory cascades in epithelial cells, prolonged
stimulation—mimicking what occurs in the intestinal
Z. WEN AND C. FIOCCHI 200milieu—results in state of prolonged hyporesponsiveness
associated with downregulation of TLR surface
expression (Otte et al., 2004). Changes in bacterial ﬂora
composition or alteration of epithelial cell surface receptor
expression could bypass these control mechanisms
that prevent excessive activation by bacteria, and result
in sustained pro-inﬂammatory signals blocking the
development of tolerance.
A genetic defect could be at the root of the issue of
broken tolerance in IBD. This, until recently, far-fetched
conjecturehas suddenlybecome a realistic possibilitywith
thediscoveryoftheassociationofCDwithmutationsofthe
NOD2/CARD15 gene on chromosome 16, the so-called
IBD1 locus (Hugot et al., 2001; Ogura et al., 2001). The
gene product of NOD2/CARD15 is a cytosolic protein that
activates NF-kB following intracellular stimulation by
bacterial products, and NOD2/CARD15 normally
functions as a general sensor of peptidoglycan through
the recognition of muramyl dipeptide, the minimal
bioactive peptidoglycan motif common to all bacteria
(Girardin et al., 2003). In view of the well established
connection between recognition of bacterial products and
CD pathogenesis, variants of the NOD2/CARD15 protein
with impaired recognition capacity and altered down-
stream signaling acquire critical importance in the
development and control of gut inﬂammation. At ﬁrst
sight, given its NF-kB activating function, it is difﬁcult to
reconciletheparadoxthatanapparent“lossoffunction”of
NOD2/CARD15resultsininﬂammation.Onepossibilityis
that the host compensates this loss of function with an
excessive or protracted activation of adaptive immunity,
and the other possibility is that the NOD2 protein does not
necessarily behave a pro-inﬂammatory molecule(Girardin
et al.,2003).Tworecentreportslendsupporttothesecond
possibility. Normal NOD2-expressing-epithelial cells are
resistant to invasion by Salmonella typhimurium, while
those carrying the CD mutations of NOD2 are unable to
constrain bacterial growth, suggesting that NOD2/
CARD15 is a component of innate immunity responses to
luminal bacteria acting as an anti-bacterial factor
(Hisamatsu et al., 2003). Moreover, NOD2-deﬁcient
mice or carrying a CD-like CARD15 mutation exhibit
increased TLR2-mediated activation of NF-kBa n d
excessive Th1 responses which may trigger inﬂammation
(Watanabe et al., 2004).
Finally, infections can break T-cell tolerance (Rocken
et al., 1992), although epidemiological or clinical
evidence that infections precede the appearance of IBD
is largely anecdotal. Nevertheless, the enormous bacterial
load of the intestinal lumen may itself play an important
role in breaking tolerance. In fact, recent studies show that
sustained exposure to bacterial antigen induces down-
regulation of the TCR z chain and impaired T-cell
function (Bronstein-Sitton et al., 2003), and activation of
FIGURE 1 Schematic diagram of autoimmune and immune-mediated events in IBD pathogenesis. Left: Self-antigens derived from intestinal epithelial
cells (hexagons), neutrophils (diamonds), and other host cells are internalized and processed by antigen-presenting cells (APC), and presented to B-cells
which produce autoantibodies such as epithelial cell-associated components (ECAC), pANCA, lymphocytotoxic antibodies, anti-pancreas antibodies,
etc. Right: Loss of tolerance to the commensal autologous ﬂora results in an enhanced reactivity against gut bacterial antigens and the inappropriate
activation of effector CD4þ helper T-cells which induce macrophage activation and production of pro-inﬂammatory cytokines. Possible causes for the
loss of tolerance include infections, excessive dendritic cell (DC) stimulation by the gut ﬂora, inadequate regulatory T-cell function, or genetic factors,
such as the CD-associated NOD2/CARD15 variants, that affect both epithelial and immune cell function.
INFLAMMATORY BOWEL DISEASE IMMUNOPATHOGENESIS 201antigen-presenting cells by microbial products via TLR
breaks self tolerance and can induce autoimmune disease
(Waldner et al., 2004).
CONCLUSIONS
Based on the available information, it seems fair to
conclude that immune-mediated appear to be more
important than autoimmune phenomena as overall
pathogenic mechanisms of IBD. It seems also fair to
conclude that some difference probably exists in regard to
the relative contribution of autoimmune vs. immune-
mediated phenomena in each form of IBD, since there is
reasonable evidence for a role of autoreactivity against
colonic epithelial cells in UC, whereas immune reactivity
against intestinal ﬂora is the prominent feature of CD
(Fig. 1). However, simply addressing the contribution of
the immune system to IBD pathogenesis, no matter in how
many exquisite details, is unlikely to provide answers to
the fundamental question of why these chronic inﬂam-
matory disorders have appeared in the last century and
their prevalence and incidence continue to raise world-
wide, affecting now populations where CD and UC were
essentially unknown until a few decades ago. All chronic
inﬂammatory diseases of unknown origin incorporate, in
addition to immune dysregulation, genetic predisposition
and environmental factors in their mechanisms of
emergence (Ermann and Fatham, 2001). Unfortunately,
the contribution of genes to disease development is still
not amenable to therapeutic intervention, and returning
our increasingly “clean” environment back to a “dirty”
one, as proposed by the hygiene hypothesis (Bach, 2002),
is not practically feasible. Thus, even though an
immunotherapeutic approach to IBD addresses the
mechanisms rather the cause of disease, the continued
investigation of autoimmune and immune-mediated
phenomena in IBD is the best hope to gain a therapeutic
handling on these devastating conditions, but this must
be done in parallel with a better understanding of
the interactions, both symbiotic and pathologic, that
occur between mucosal immunity and the commensal
enteric ﬂora.
References
Aichbichler, B.W., Petritsch, W., Reicht, G.A., Wenzel, H.H.,
Eherer, A.J., Hinterleitner, T.A., et al. (1999) “Anti-cardiolipin
antibodies in patients with inﬂammatory bowel disease”, Dig. Dis.
Sci. 44, 852–856.
Aronson, R.A., Cook, S.L. and Roche, J.K. (1983) “Sensitization to
epithelial antigens in chronic mucosal inﬂammatory disease.
I. Puriﬁcation, characterization, and immune reactivity of murine
epithelial cell-associated components (ECAC)”, J. Immunol. 131,
2796–2804.
Bach, J-F. (2003) “Regulatory cells under scrutiny”, Nat. Rev. 3,
189–198.
Bach, J-F. (2002) “The effect of infections an susceptibility to
autoimmune and allergic diseases”, N. Engl. J. Med. 347, 911–920.
Bhagat, S. and Das, K.M. (1994) “A shared and unique epitope in the
human colon, eye and joint detected by a monoclonal antibody”,
Gastroenterology 107, 103–108.
Biancone, L., Mandal, A., Yang, H., Dasgupta, T., Paoluzi, A.O.,
Marcheggiano, A., et al. (1995) “Production of immunoglobulin G
and G1 antibodies to cytoskeletal protein by lamina prorpia cells in
ulcerative colitis”, Gastroenterology 109, 3–12.
Bjorksten, B., Sepp, E., Julge, K., Voor, T. and Mikelsaar, M. (2001)
“Allergy development and the intestinal microﬂora during the ﬁrst
years of life”, J. Allergy Clin. Immunol. 108, 516–520.
Blaser, M.J., Miller, R.A., Lacher, J. and Singleton, J.W. (1984) “Patients
with active Crohn’s disease have elevated serum antibodies to
antigens of seven enteric bacterial pathogens”, Gastroenterology 87,
888–894.
Bouma, G. and Strober, W. (2003) “The immunological and genetic basis
of inﬂammatory bowel disease”, Nat. Rev. Immunol 3, 521–533.
Broberger, O. and Perlmann, P. (1959) “Autoantibodies in human
ulcerative colitis”, J. Exp. Med. 110, 657–674.
Bronstein-Sitton, N., Cohen-Daniel, L., Vakin, I., Ezernitchi, A.V.,
Leshen, B., Halabi, H., et al. (2003) “Sustained exposure to bacterial
antigens induces interferon-g-dependent T cell receptor h down-
regulation and impaired T cell function”, Nat. Immunol. 4, 957–964.
Bull, D.M. and Ignaczak, T.F. (1973) “Enterobacterial common antigen-
induced lymphocyte reactivity in inﬂammatory bowel disease”,
Gastroenterology 64, 43–50.
Casare, C. and Medzhitov, R. (2003) “Toll pathway-dependent blockade
of CD4þ CD25þ T cell-mediated suppression by dendritic cells”,
Science 299, 1033–1036.
Cebra, J.J., Periwal, S.B., Lee, G. and Shroff, K.E. (1998) “Development
and maintenance of the gut-associated lymphoid tissue (GALT): the
roles of enteric bacteria and viruses”, Dev. Immunol. 6, 13–18.
Cong, B.Y., Brandwein, S.L., McCabe, R.P., Lazenby, A., Birkenmeier,
E.H., Sundberg, J.P., et al. (1998) “CD4þ T cells reactive to enteric
bacterial antigens in spontaneously colitic C3H/HeJBir mice:
increased T helper cell type 1 response and ability to transfer
disease”, J. Exp. Med. 187, 855–864.
Dalwadi, H., Wei, B., Kronenberg, M., Sutton, C.L. and Braun, J. (2001)
“The Crohn’s disease-associated bacterial protein I2 is a novel enteric
T cell superantigen”, Immunity 15, 149–158.
Das, K.M., Sakamaki, S., Vecchi, M. and Diamond, B. (1987) “The
production and characterization of monoclonal antibodies to a human
colonic antigen associated with ulcerative colitis: cellular localization
of the antigen by using the monoclonal antibody”, J. Immunol. 139,
77–84.
Das, K.M., Vecchi, M. and Sakamaki, S. (1990) “A shared and unique
epitope(s) on human colon, skin, and biliary epithelium detected by a
monoclonal antibody”, Gastroenterology 98, 464–469.
Das, K.M. (1999) “Relationship of extraintestinal involvements in
inﬂammatory bowel disease. New insights into autopimmune
pathogenesis”, Dig. Dis. Sci. 44, 1–13.
Das, K.M., Dasgupta, A., Mandal, A. and Geng, X. (1993)
“Autoimmunity to cytoskeletal protein tropomyosin. A clue to the
pathogenetic mechanisms for ulcerative colitis”, J. Immunol. 150,
2487–2493.
Doe, W.F., Booth, C.C. and Brown, D.L. (1973) “Evidence for
complement-binding immune complexes in adult coeliac disease,
Crohn’s disease and ulcerative colitis”, Lancet 24, 402–403.
Duchmann, R., Kaiser, I., Hermann, E., Mayet, W., Ewe, K. and Meyer
zum Buschenfelde, K.H. (1995) “Tolerance exists towards resident
intestinal ﬂora but it is broken in active inﬂammatory bowel disease
(IBD)”, Clin. Exp. Immunol. 102, 448–455.
Duchmann, R., Schmitt, E., Knolle, P., Meyer zum Buschenfelde, K.H.
and Neurath, M. (1996) “Tolerance towards resident intestinal ﬂora in
mice is abrogated in experimental colitis and restored by treatment
with interlukin-10 or antibodies to interleukin-12”, Eur. J. Immunol.
26, 934–938.
Duchmann, R., May, E., Heike, M., Knolle, P., Neurath, M. and Meyer
zum Buschenfelde, K.H. (1999) “T cell speciﬁcity and cross
reactivity towards enterobacteria, Bacteroides, Biﬁdobacterium, and
antigens from resident intestinal ﬂora in humans”, Gut 44, 812–818.
Duerr, R.H., Targan, S.R., Landers, C.J., Sutherland, L.R. and
Shanahan, F. (1991) “Anti-neutrophil cytoplasmic antibodies in
ulcerative colitis. Comparison with other colitides/diarrheal
diseases”, Gastroenterology 100, 1590–1596.
Ermann, J. and Fatham, C.G. (2001) “Autoimmune diseases: genes, bugs
and failed regulation”, Nat. Immunol. 2, 759–761.
Fabia, R., ArRajab, A., Andersson, M-L., Willen, R., Jeppsson, B.,
Molin, G. and Bengmark, S. (1993) “Impairement of bacterial ﬂora
in human ulcerative colitis and experimental colitis in the rat”,
Digestion 54, 248–255.
Z. WEN AND C. FIOCCHI 202Favier, C.F., Vaughan,E.E., DeVos, W.M. and Akkermans,A.D.L. (2002)
“Molecular monitoring of succession of bacteria communities in
human neonates”, Appl. Environ. Microbiol. 68, 219–226.
Fiocchi, C. (1998) “Inﬂammatory bowel disease: etiology and
pathogenesis”, Gastroenterology 115, 182–205.
Fricke, H., Birkhofer, A., Folwaczny, C., Meister, W. and Scriba, P.C.
(1999) “Characterization of antigens from the human exocrine
pancreatic tissue (Pag) relevant as target antigens for autoantibodies
in Crohn’s disease”, Eur. J. Clin. Investig. 29, 41–45.
F u s s ,I . J . ,H e l l e r ,F . ,B o i r i v a n t ,M . ,L e o n ,F . ,Y o s h i d a ,M . ,
Fichtner-Feigi, S., et al. (2004) “Nonclassical CD1d-restricted NK
T cells that produce IL-13 characterize an atypical Th2 response in
ulcerative colitis”, J. Clin. Investig. 113, 1490–1497.
Geng, X., Biancone, L., Dai, H.H., Lin, J.J.C., Yoshizaki, N., Dasgupta,
A., et al. (1998) “Tropomyosin isoform in intestinal mucosa:
production of autoantibodies to tropomyosin isoforms in ulcerative
colitis”, Gastroenterology 114, 912–922.
Giaffer, M.H., Clark, A. and Holdsworth, C.D. (1992) “Antibodies to
Saccharomyce cerevisiae in patients with Crohn’s disease and their
possible pathogenic importance”, Gut 33, 1071–1075.
Girardin, S.E., Boneca, I.G., Viala, J., Chamaillard, M., Labigne, A.,
Thomas, G., et al. (2003) “Nod2 is a general sensor of peptidoglycan
through muramyl dipeptide (MDP) detection”, J. Biol. Chem. 278,
8869–8872.
Girardin, S.E., Hugot, J.P. and Sansonetti, P.J. (2003) “Lessons from
Nod2 studies: towards a link between Crohn’s disease and bacterial
sensing”, Trends Immunol. 24, 652–658.
Groux, H., O’Garra, A., Bigler, M., Rouleau, M., Antonenko, S., deVries,
J.E., et al. (1997) “A CD4þ T-cell subset inhibits antigen-speciﬁc
T-cell responses and prevents colitis”, Nature 389, 737–742.
Guarnier, F. and Malagelada, J.R. (2003) “Gut ﬂora in health and
disease”, Lancet 361, 512–519.
Halstensen, T.S., Mollnes, T.E. and Brandtzaeg, P. (1989) “Persistent
complement activation in submucosal vessels of active inﬂammatory
bowel disease: immunohistochemical evidence”, Gastroenterology
97, 10–19.
Halstensen, T.S., Das, K.M. and Brandtzaeg, P. (1993) “Epithelial
deposits of immunoglobulin G1 and activated complement colocalise
with the Mr 40kDa putativeautoantigen in ulcerative colitis”, Gut 34,
650–657.
Hisamatsu, T., Suzuki, M., Reinecker, H.C., Nadeau, W.J.,
McCormick, B.A. and Podolsky, D.K. (2003) “CARD15/NOD2
functions as an antibacterial factor in human intestinal epithelial
cells”, Gastroenterology 124, 993–1000.
Hooper, L.V. and Gordon, J.I. (2001) “Commensal host-bacterial
relationships in the gut”, Science 292, 1115–1118.
Hooper, L.V., Wong, M.H., Thelin, A., Hansson, L., Falk, P.G. and
Gordon,J.I. (2001) “Molecular analysisof commensalhost-microbial
relationships in the intestine”, Science 291, 881–884.
Hornef, M.W., Wick, M.J., Rhen, M. and Normark, S. (2002) “Bacterial
strategies for overcoming host innate and daptive immune
responses”, Nat. Immunol. 3, 1033–1040.
Hugot, J.P., Chamaiilard, M., Zouali, H., Lesage, S., Cezard, J.P.,
Belaiche, J., et al. (2001) “Association of NOD2 leucine-rich repeat
variants with susceptibility to Crohn’s disease”, Nature 411,
599–603.
Jewell, D.P. and McLennan, I.C.M. (1973) “Circulating immune
complexes in inﬂammatory bowel disease”, Clin. Exp. Immunol.
14, 219–226.
Khoo, U.Y., Proctor, I.E. and Macpherson, A.J.S. (1997) “CD4þ T cell
down-regulation in human intestinal mucosa. Evidence for intestinal
tolerance to luminal bacterial antigens”, J. Immunol. 158,
3626–3634.
Kirjavainen, P.V., Arvola, T., Dalminen, S.J. and Isolauri, E. (2002)
“Aberrant composition of gut microbiota of allergic infants: a target
of biﬁdobacterial therapy at weaning?”, Gut 51, 51–55.
Korsmeyer, S., Strickland, R.G., Wilson, I.D. and Williams, R.C. (1974)
“Serum lymphocytotoxic and lymphocytophilic antibody activity in
inﬂammatory bowel disease”, Gastroenterology 67, 578–583.
Kraus, T.A., Toy, L., Chan, L., Childs, J. and Mayer, L. (2004)
“Failure to induce oral tolerance to a soluble protein in patients
with inﬂammatory bowel disease”, Gastroenterology 126,
1771–1778.
Landers, C.J., Cohavy, O., Misra, R., Huiying, H., Lin, Y.C., Braun, J.,
et al. (2002) “Selected loss of tolerance evidenced by Crohn’s
disease-associated immune responses to auto- and microbial
antigens”, Gastroenterology 123, 689–699.
Liu, Y.J. (2001) “Dendritic cell subsets and lineages, and their functions
in innate and adaptive immunity”, Cell 106, 259–262.
Lodes, M.J., Cong, Y., Elson, C.O., Mohamath, R., Landers, C.J.,
Targan, S.R., et al. (2004) “Bacterial ﬂagellin is a dominant antigen
in Crohn disease”, J. Clin. Investig. 113, 1296–1306.
Lu, J., Wang, A., Ansari, S., Hershberg, R.M. and McKay, D.M. (2003)
“Colonic bacterial superantigens evoke an inﬂammatory response
and exaggerate disease in mice recovering from colitis”,
Gastroenterology 125, 1785–1795.
MacDermott, R.P., Nash, G.S., Bertovich, M.J., Seiden, M.V., Bragdon,
M.J. and Beale, M.G. (1981) “Alterations of IgM, IgG, and IgA
synthesis and secretion by peripheral blood and intestinal
mononuclear cells from patients with ulcerative colitis and Crohn’s
disease”, Gastroenterology 81, 844–852.
Macpherson, A., Khoo, U.Y., Forgacs, I., Philipott-Howard, J. and
Bjarnarson, I. (1996) “Mucosal antibodies in inﬂammatory
bowel disease are directed against intestinal bacteria”, Gut 38,
365–375.
Mandal,A.,Dasgupta,A., Jeffers, L.,Squillante,L.,Hyder, S.,Reddy, R.,
et al. (1994) “Autoantibodies in sclerosing cholangitis against a
shared peptide in biliary and colon epithelium”, Gastroenterology
106, 185–192.
Marrack, P., Kappler, J. and Kotzin, B.L. (2001) “Autoimmune disease:
why and where it occurs”, Nat. Med. 7, 899–905.
Mayet, W.J., Press, A.G., Hermann, E., Moll, R., Manns, M., Ewe, K. and
MeyerzumBuschenfelde, K.H. (1990) “Antibodies to cytoskeletal
proteins in patients with Crohn’s disease”, Eur. J. Clin. Investig. 20,
516–524.
McKenzie, H., Main, J., Pennington, C.R. and Parratt, D. (1990)
“Antibody to selected strains of Saccharomyces cerevisiae (baker’s
and brewer’ yeast) and Candida albicans in Crohn’s disease”, Gut 31,
536–538.
Melmed, G., Thomas, L.S., Lee, N., Tesfay, S.Y., Lukasek, K.,
Michelsen, K.S., et al. (2003) “Human intestinal epithelial cells are
broadly unresponsive to toll-like receptor 2-dependent bacterial
ligands: implications for host-microbial interactions in the gut”,
J. Immunol. 170, 1406–1415.
Misra, N., Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M.D. and
Kaveri, S.V. (2004) “Human CD4þ CD25þ T cells restrain the
maturation and antigen-presenting function of dentritic cells”,
J. Immunol. 172, 4676–4680.
Mizoguchi, E., Mizoguchi, A., Chiba, C., Niles, J.L. and Bhan, A.K.
(1997) “Antineutrophil cytoplasmic antibodies in T-cell receptor
a-deﬁcient mice with chronic colitis”, Gastroenterology 113,
1828–1835.
Monteiro,E., Fossey, J., Shiner, M., Drasar, B.S. andAllison,A.C. (1971)
“Antibacterial antibodies in rectal and colonic mucosa in ulcerative
colitis”, Lancet i, 249–251.
Monteleone, G., Biancone, L., Marasco, R., Morrone, G., Marasco, O.,
Luzza, F., et al. (1997) “Interleukin 12 is expressed and actively
released by Crohn’s disease intestinal lamina propria mononuclear
cells”, Gastroenterology 112, 1169–1178.
Monteleone, I., Vavassori, P., Biancone, L., Monteleone, G. and
Pallone, F. (2002) “Immunoregulation in the gut: success and failures
in human disease”, Gut 50(Suppl III), iii60–iii64.
Mottet, C., Uhlig, H.H. and Powrie, F. (2003) “Cure of colitis by
CD4
þCD25
þ regulatory T cells”, J. Immunol. 170, 3939–3943.
Mow, W.S., Vasiliauskas, E.A., Lin, Y.C., Fleshner, P.R., Papadakis,
K.A., Taylor, K.D., et al. (2004) “Association of antibody responses
to microbial antigens and complications of small bowel Crohn’s
disease”, Gastroenterology 126, 414–424.
Neurath, M.F., Finotto, S. and Glimcher, L.H. (2002) “The role of
Th1/Th2 polarization in mucosal immunity”, Nat. Med. 8, 567–573.
Ogawa, H., Fukushima, K., Sasaki, I. and Matsuno, S. (2000)
“Identiﬁcation of genes involved in mucosal defense and inﬂam-
mation associated with normal enteric bacteria”, Am. J. Physiol. 279,
G492–G499.
Ogura, Y., Bonen, D.K., Inohara, N., Nicolae, D.L., Chen, F.F., Ramos,
R., et al. (2001) “A frameshift mutation in Nod2 associated with
susceptibility to Crohn’s disease”, Nature 411, 603–606.
Otte, J.M., Cario, E. and Podolsky, D.K. (2004) “Mechanisms of cross
hyporesponsiveness to toll-like receptor bacterial ligands in intestinal
epithlial cells”, Gastroenterology 126, 1054–1070.
Pallone, F., Matricardi, P.M., Squarcia, O., Fais, S., LeMoli, S.,
Boirivant, M., et al. (1986) “Raised serum levels of IgM-rheumatoid
factor and anti-F(ab0)2 autoantibodies in patients with active
inﬂammatory bowel disease”, J. Clin. Lab. Immunol. 19, 175–180.
INFLAMMATORY BOWEL DISEASE IMMUNOPATHOGENESIS 203Perlmann, P. and Broberger, O. (1963) “In vitro studies of ulcerative
colitis. II. Cytotoxic action of white blood cells from patients on
human fetal colon cells”, J. Exp. Med. 117, 717–733.
Perlmann,P., Hammarstrom, S.,Lagercrantz, R. and Campbell,D. (1967)
“Autoantibodies to colon in rats and human ulcerative colitis: cross
reactivity with Escherichia coli O:14 antigen”, Proc. Soc. Exp. Biol.
Med. 125, 975–980.
Pirzer, U., Schonhaar, A., Fleischer, B., Hermann, E. and Meyer zum
Buschenfelde, K.H. (1991) “Reactivity of inﬁltrating T lymphocytes
with microbial antigens in Crohn’s disease”, Lancet 338, 1238–1239.
Podolsky, D.K. (2002) “Inﬂammatory bowel disease”, N. Engl. J. Med.
347, 417–429.
Quinton, J.F., Sendid, B., Reumaux, D., Duthilleul, P., Cortot, A.,
Grandbastien, B., et al. (1998) “Anti-Saccharomyces cerevisiae
mannan antibodies combined with antineutrophil cytoplasmic
autoantibodies in inﬂammatory bowel disease: prevalence and
diagnostic role”, Gut 42, 788–791.
Rath, H.C., Ikeda, J.S., Linde, H.J., Scholmerich, J., Wilson, K.H. and
Sartor, R.B. (1999a) “Varying cecal bacterial loads inﬂuences colitis
and gastritis in HLA-B27 transgenic rats”, Gastroenterology 116,
310–319.
Rath,H.C.,Wilson, K.H.andSartor, R.B.(1999b)“Differential induction
of colitis and gastritis in HLA-B27 trangenic rats selectively
colonized with Bacteroides vulgatus or Escherichia coli”, Infect.
Immunol. 67, 2969–2974.
Rescigno, M., Urbano, M., Valzasina, B., Francolini, M., Rotta, G.,
Bonasio, R., et al. (2001) “Dendritic cells express tight junction
proteins and penetrate gut epithlial monolayers to sample bacteria”,
Nat. Immunol. 2, 361–367.
Roche, J.K., Cook, S.L. and Day, E.D. (1981) “Goblet cell glycoprotein:
an organ-speciﬁc antigen for the gut. Isolation, tissue localization and
immune response”, Immunology 44, 799–810.
Roche, J.K., Fiocchi, C. and Youngman, K. (1985) “Sensitization to
epithelial antigens in chronic mucosal inﬂammatory disease.
Characterization of human intestinal mucosa-derived mononuclear
cells reactive with puriﬁed epithelial cell-associated components
in vitro”, J. Clin. Investig. 75, 522–530.
Rocken, M., Urban, J.F. and Shevach, E.M. (1992) “Infection breaks
T-cell tolerance”, Nature 359, 79–82.
Roncarolo, M.G., Bacchetta, R., Bordignon, C., Narula, S. and Levings,
M.K. (2001) “Type 1 regulatory cells”, Immunol. Rev. 182, 68–79.
Rose, N.R. and Bona, C. (1993) “Deﬁning criteria for autoimmune
diseases (Witebsky’s postulates revisited)”, Immunol. Today 14,
426–430.
Ruemelle, F.M., Targan, S.R., Levy, G., Dubinsky, M., Braun, J. and
Seidman, E.G. (1998) “Diagnostic accuracy of serological assays in
pediatric inﬂammatory bowel disease”, Gastroenterology 115,
822–829.
Saxon, A., Shanahan, F., Landers, C., Ganz, T. and Targan, S. (1990)
“A distinct subset of anti-neutrophil cytoplasmic antibodies is
associated with inﬂammatory bowel disease”, J. Allergy Clin.
Immunol. 86, 202–210.
Schultsz, C., VandenBerg, F.M., Kate, F.W.T., Tytgat, G.N.J. and
Dankert, J. (1999) “The intestinal mucus layer from patients with
inﬂammatory bowel disease harbors high numbers of bacteria
compared with controls”, Gastroenterology 117, 1089–1097.
Seibold, F., Brandwein, S., Simpson, S., Terhorst, C. and Elson, C.O.
(1998) “pANCA represents a cross-reactivity to enteric bacterial
antigens”, J. Clin. Immunol. 18, 153–160.
Seksik, P., Rigottier-Gois, L., Gramet, G., Sutren, M., Pochart, P.,
Marteau, P., et al. (2003) “Alterations of the dominant faecal
bacterial groups in patients with Crohn’s disease of the colon”, Gut
52, 237–242.
Shanahan, F. (1994) “Neutrophil autoantibodies in inﬂammatory bowel
disease: are they important?”, Gastroenterology 107, 586–589.
Snook, J. (1990) “Are the inﬂammatory bowel diseases autoimmune
disorders?”, Gut 31, 961–963.
Staag, A.J., Hart, A.L., Knight, S.C. and Kamm, M.A. (2003) “The
dendritic cell: its role in intestinal inﬂammation and relationship with
gut bacteria”, Gut 52, 1522–1529.
Straub, R.H. and Besedovsky, H.O. (2003) “Integrated evolutionary,
immunological, and neuroendocrine framework for the pathogenesis
of chronic disabling inﬂammatory diseases”, FASEB J. 17,
2176–2183.
Sugi, K., Saitoh, O., Matsuse, R., Tabata, K., Uchida, K., Kojima, K.,
et al. (1999) “Antineutrophil cytoplasmic antibodies in Japanese
patients with inﬂammatory bowel disease: prevalence and recog-
nition of putative antigens”, Am. J. Gastroenterol. 94, 1304–1312.
Sutton, C.L., Kim, J., Yamane, A., Dalwadi, H., Wei, B., Landers, C.,
et al. (2000) “Identiﬁcation of a novel bacterial sequence associated
with Crohn’s disease”, Gastroenterology 119, 23–31.
Swidsinski, A., Ladhoff, A., Pernthaler, A., Swidsinski, S., Loening-
Baucke, V., Ortner, M., et al. (2002) “Mucosal ﬂora in inﬂammatory
bowel disease”, Gastroenterology 122, 44–54.
Tabaqchali, S., O’Donaghue, D.P. and Bettelheim, K.A. (1978)
“Escherichia coli antibodies in patients with inﬂammatory bowel
disease”, Gut 19, 108–113.
Takahashi, F. and Das, K.M. (1985) “Isolation and characterization of a
colonic autoantigen speciﬁcally recognized by colon tissue-bound
immunoglobulin G from idiopathic ulcerative colitis”, J. Clin.
Investig. 76, 311–318.
Takeda, K., Kaisho, T. and Akira, S. (2003) “Toll-like receptors”, Annu.
Rev. Immunol. 21, 335–376.
Taurog, J.D., Richardson, J.A., Croft, J.T., Simmons, W.A., Zhou, M.,
Fernandez-Sueiro, J.L., et al. (1994) “The germfree state prevents
development of gut and joint inﬂammatory disease in HLA-B27
transgenic rats”, J. Exp. Med. 180, 2359–2364.
Thayer, W.R. (1976) “Are the inﬂammatory bowel diseases immune
complex diseases?”, Gastroenterology 70, 136–137.
Toms, C. and Powrie, F. (2001) “Control of intestinal inﬂammation by
regulatory cells”, Microbes Infect. 3, 929–935.
VandeMerwe, J.P., Schroder, A.M., Wensinck, F. and Hazenberg, M.P.
(1988) “The obligate anaerobic faecal ﬂora of patients with Crohn’s
disease and their ﬁrst-degree relatives”, Scand. J. Gastroenterol. 23,
1125–1131.
Vezys, V. and Lefranc ¸ois, L. (2002) “Inﬂammatory signals drive organ-
speciﬁc autoimmunity to normally cross-tolerizing endogenous
antigen”, J. Immunol. 169, 6677–6680.
Waldner, H., Collins, M. and Kuchroo, V.K. (2004) “Activation of
antigen-presenting cells by microbial products breaks self
tolerance and induces autoimmune disease”, J. Clin. Investig. 113,
990–7.
Watanabe, T., Kitani, A., Murray, P.J. and Strober, W. (2004) “NOD2 is a
negative regulator of toll-like receptor 2-mediated T helper type 1
responses”, Nat. Immunol., (advanced on line publication).
Winter, H.S., Crum, P.M., King, N.W., Seghal, P.K. and Roche, J.K.
(1989) “Expression of immune sensitization to epithelial cell-
associated components in the cotton-top tamarin: a model of chronic
ulcerative colitis”, Gastroenterology 97, 1057–1082.
Wirtz, S., Finotto, S., Kanzler, S., Lohse, A.W., Blessing, M., Lehr, H.A.,
et al. (1999) “Chronic intestinal inﬂammation in STAT-4 transgenic
mice: characterization of disease and adoptive transfer by TNF- plus
IFN-g-producing CD4þ T cells that respond to bacterial antigens”,
J. Immunol. 162, 1884–1888.
Wucherpfennig, K.W. (2001) “Mechanisms for the induction of
autoimmunity by infectious agents”, J. Clin. Investig. 108,
1097–1104.
Young, C.A., Sonnenberg, A. and Burns, E.A. (1994) “Lymphocyte
proliferation to baker’s yeast in Crohn’s disease”, Digestion 55,
40–43.
Z. WEN AND C. FIOCCHI 204